You are here:

Home
NICE Guidance
Conditions and diseases
Cancer
Bladder cancer

Bladder cancer Products

A list of all our products on bladder cancer

Filter

Product type

Product typeGuidanceQuality standardsAdvice

Guidance programme

Guidance programmeNICE guidelinesTechnology appraisal guidanceDiagnostics guidanceHealthTech guidanceInterventional procedures guidanceMedical technologies guidance

Status
1 selected

StatusPublishedIn consultationIn developmentAwaiting developmentTopic prioritisation

New and updated

New and updatedNew in the last 6 monthsUpdated in the last 6 months

Showing 2 products

Sort by: Date | Sort by Title

Status: In consultationRemove ‘Status: In consultation’ filter

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer [ID6168]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
10 February 2026
Expected publication date:
2 March 2026
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
20 February 2026
Expected publication date:
TBC